Specify a stock or a cryptocurrency in the search bar to get a summary
Cognition Therapeutics Inc
CGTXCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York. Address: 2500 Westchester Ave., Purchase, NY, United States, 10577
Analytics
WallStreet Target Price
6.2 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CGTX
Dividend Analytics CGTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CGTX
Stock Valuation CGTX
Financials CGTX
Results | 2019 | Dynamics |